Drugmaker Fine Shows SEC's Renewed Disclosure Focus
On Aug. 20, pharmaceutical company TherapeuticsMD Inc. settled charges by the U.S. Securities and Exchange Commission that the company had selectively disclosed market-moving information to sell-side analysts regarding potential approval of...To view the full article, register now.
Already a subscriber? Click here to view full article